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Protein C is a vitamin Krdependent serine prortease and naturally occurring anticoagulant that plays a role in the regulation of hemostasis by 
inactivating factors Va and VIIIa in the coagulation casr
cade. Human protein C circulates as a 2rchain zymor
gen, but functions at the endothelial and platelet surface 
following conversion to activated protein C by limited 
proteolysis with thrombin in complex with the cell surr
face membrane protein, thrombomodulin.1 
Thalassemias are inherited hemoglobinopathies 
characterized by a structural hemoglobin defect. These 
hereditary diseases have significant morbidity and morr
tality and affect individuals of AfricanrAmerican herir
tage, as well as those of Mediterranean, Middle Eastern, 
and Southeast Asian descent.2 
 Despite the difficulties associated with treatment, 
standards of care for thalassemic patients have improved 
in recent years, resulting in almost a doubling of the avr
erage life expectancy. As a consequence, additional prer
viously undescribed complications are now being recogr
nized. In particular, profound hemostatic changes have 
been observed in patients with brthalassemia major, esr
pecially splenectomized cases. The presence of a higher 
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BACKGROUND AND OBjECTIvES: thalassemic patients have an increased risk for thromboembolic complica-
tions. to determine if this might be due to a deficiency in protein c, we investigated the status of the protein c 
anticoagulant pathway in thalassemia major patients and its relationship to the hypercoagulable state. 
PATIENTS AND METHODS: fifty patients with b-thalassemia major (30 non-splenectomized and 20 splenecto-
mized) and 20 healthy children as a control group were tested for levels of serum ferritin, liver enzymes, serum 
albumin, fibrinogen, protein c and protein s, thrombin antithrombin complex (tat) and d-dimer. 
RESULTS: thalassemic patients had lower levels of protein c and s and higher levels of d-dimer and tat than 
the control group. these findings were more obvious in splenectomized patients and in those with infrequent 
blood transfusion. 
CONCLUSIONS: protein c plays a major role in the hypercoagulable state in thalassemic patients. these find-
ings raise the issue as to whether it would be cost-beneficial to recommend prophylactic antithrombotic therapy 
in high-risk thalassemic patients. a wider prospective study is necessary to delineate under which circum-
stances therapy might be needed, and at what level of protein c deficiency to start prophylactic antithrombotic 
therapy.
than normal incidence of thromboembolic events and 
the existence of prothrombotic hemostatic anomalies in 
the majority of the patients, even from a very young age, 
have led to the recognition of the existence of a chronic 
hypercoagulable state in thalassemic patients.3 
 Several etiologic factors may play a role in the 
pathogenesis of the hypercoagulable state in thalasser
mia such as platelet activation and increased circulatr
ing aggregates,4,5 shortened platelet survival,6 increased 
urinary excretion of thromboxane A2 and prostacyclin 
metabolites,7 decreased levels of naturally occurring anr
ticoagulants such as protein C and protein S, and an elr
evated plasma level of thrombinrantithrombin complex 
have also been reported.8,9 A mechanism involving the 
loss of membrane phospholipid asymmetry in thalasr
semic red or erythroid cells, with the exposure of pror
coagulant phosphatidylserine in the outer leaflet of the 
red cell membrane has also been proposed.10 
 The lower protein C levels in thalassemia are either 
due to decreased production or increased consumption. 
Therefore, a coagulation imbalance exists in patients 
with thalassemia, which in turn may be responsible for 
the adverse clinical effects observed in those patients.2 
original research reportprOTein C in b-THalaSSeMiC
Hematol Oncol Stem Cell Ther 3(2)     Second Quarter 2010 hemoncstem.edmgr.com 61
We investigated the status of the protein C anticoagur
lant pathway in thalassemic patients and its relationship 
to the hypercoagulable state in thalassemia major.
PATIENTS AND METHODS
In this casercontrol study we included 50 patients with 
brthalassemia major (29 males and 21 females) and 20 
healthy children matched by sex and age, who were ser
lected as a control group. Subjects were classified into 
group NS (30 patients with thalassemia major and 
nonrsplenectomized), group S (20 splenectomized 
thalassemia major patients), and group C (20 healthy 
subjects as a control group). Subjects were excluded 
for liver enzymes more than 5 times normal range, 
hepatitis C and/or B positivity, cormorbid conditions 
known to alter hemostasis, recent infection, or recent 
administration of aspirin or drugs that affect haemor
static function. None of our patients had a history of 
thrombosis including thrombophlebitis due to per
ripheral angiocatheter insertion. For every subject, we 
took a complete history, performed a thorough clinical 
examination, and performed routine investigations as 
well as an estimation of serum ferritin, liver enzymes, 
serum albumin, fibrinogen level, protein C and protein 
S levels, thrombin antithrombin complex and Drdir
mer. 
Blood samples from groups NS and S were collectr
ed immediately before blood transfusion. Protein C, 
protein S, TAT, fibrinogen and Drdimer assay, citrated 
plasma was prepared as follows: blood samples were 
collected in tubes containing 3.2% sodium citrate as 
anticoagulant (9:1 ratio) and centrifuged at 2000g for 
15 minutes to collect the plasma and the samples were 
stored at r80ºC until the time of assay. Protein C assay 
was measured using REAADS protein C antigen test 
kit (Corginex Inc, Colorado, USA). Protein S assay 
was measured using REAADS protein S antigen test 
kit (Corginex Inc. Colorado, USA). Both assays were 
performed using Sandwich ELISA technique (Behring 
ELISA processor P instrument). Plasma TAT levels 
were measured using Enzygnost TAT micro ELISA 
kits (Dade Behring Inc. New York, USA). The assay 
was also performed using the Sandwich ELISA techr
nique by Behring ELISA processor P instrument. Dr
dimer assay was measured using VIDAS Drdimer exr
clusion kits (bioMérieux Inc. France), for the immune 
enzymatic determination of fibrin degradation prodr
ucts (FbDP) in plasma using ELFA technique (Vidas 
pc instrument, bioMérieux Inc. France).
  STATA version 6.0 was used for data analysis 
(StataCorp, College Station, Texas, USA).Where apr
plicable, the mean (standard deviation) of the results 
are shown. Onerway analysis of variance (ANOVA) 
was used to assess differences among means of the 
three groups. Assumptions of onerway ANOVA, i.e. 
normal distribution and homoscedasticity of the data, 
were checked, and the raw data were transformed to 
an appropriate scale, such as log scale, to meet these 
assumptions. If the onerway ANOVA showed statistir
cally significant differences among groups, each group 
was paired with the others and differences between 
the groups assessed by the Scheffe test. A statistically 
significant difference was defined as P<.05. Stepwise 
multiple regression analysis was used to assess the inr
fluence of multiple variables on a single variable, enr
tering those variables that correlated significantly with 
the single variable by univariate analysis.11 
RESULTS
The 30 nonrsplenectomized thalassemic patients had 
a median age of 11.5 years; there were 16 males and 
14 females; 6 patients with regular blood transfur
sions (12 times/year) and 24 patients with infrequent 
blood transfusions (<12 times /year). The 20 splenecr
tomized thalassemic patients had a median age of 12 
years; there were 13 males and 7 females; 3 patients 
had regular blood transfusions and 17 had infrequent 
blood transfusions. The 20 healthy children had a 
median age of 12 years; there were 13 males and 7 fer
males.
Serum ferritin, AST, and ALT were significantly 
higher in groups NS and S versus group C (Table 1). 
Plasma levels of protein C and protein S were signifir
cantly lower in NS and S groups than in the C group. 
Plasma levels of TAT and Drdimer were significantly 
higher in NS and S groups than in NC group. There 
was a significant decrease in protein C and protein S 
in the S group compared to the NS group (Table 2), 
while there was significant increase in TAT and Drdir
mer levels in the S group compared to the NS group. 
Thalassemic patients with regular blood transfur
sions, whether NS or S, had higher levels of protein 
C than their peers with infrequent blood transfusion 
(Table 3). This finding was also present with pror
tein S, while Drdimer levels were lower in frequently 
transfused patients than infrequently transfused ones 
in both groups. Although TAT levels were lower in 
frequently transfused patients than infrequently transr
fused ones in the NS group, the difference was not star
tistically significant.
Forty percent of patients had pulmonary hypertenr
sion detected by Doppler echocardiogram (Table 4). 
Most of these patients (80%) belonged to the splenecr
tomized and infrequently transfused group. Also, there 
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Table 1. laboratory data for patients and controls.
Group NS
(n=30)
Group S
(n=20)
Group C 
(n=20) F P
   Ferritin (ng/ml) 1838.7 (899)(870-3500)
2811.8 (589.8)
(1000-3200)
221 (36.8)
(150-300) 42.2 <.001
   albumin (gm\dl) 3.5 (0.5)(2.7-4.2)
3.6 (0.23)
(2.9-4.4)
4 (0.4)
(3-4.6) -4.9 >.05
   aspartate aminotransferase 
   (mg\dl) 
75.6 (32.4)
(32-201)
86.2 (36.9)
(46-200)
37.4 (14.1)
(20-89) 15.8 <.001
   alanine aminotransferase    
   (mg\dl)
79.8 (26.4)
(45-180)
89.2 (38.2)
(45-185)
38.7 (14.1)
(24-90) 20.29 <.001
   protein C (%) 72.36 (10.3)(53-92)
57.7 (15.8)
(40-108)
97.9 (13.2)
(50-120) 51.1 <.001
   protein S (%) 73.1 (8.7)(59-85)
62.4 (56.2)
(48-100)
97.9 (12.7)
(55-120) 54.1 <.001
   TaT (μg\l) 12.36 (3)(9-20)
15.9 (2.6)
(12.4-21)
6.3 (2.7)
(2.8-17) 58.4 <.001
   d-dimer 103 (ng/ml) 3 (1.5)(0-8)
5.47 (2)
(0-8)
0.28 (1.3)
(0-6) 50.2 <.001
Values are mean (Sd) and range in parentheses. F=anOVa test (analysis of variance) for comparison of several means.  The P value is for the difference between the control and 
either group a or B.
Table 2. Hemostatic and thrombotic markers in non-splenectomized and splenectomized beta-thalassemic 
patients.
Group NS
(n=30)
Group S
(n=20) t P
   protein C (%) 72.36 (10.3) 57.7 (15.8) 3.9 .001
   protein S (%) 73.1 (8.7) 62.4 (56.2) 3.4 .001
   TaT (μg/l) 12.36 (3) 15.9 (2.6) -4.2 .001
   d-dimer 103 (ng/ml) 3 (1.5) 5.47 (2) -4.6 .001
Values are mean (standard deviation).
Table 3. Hemostatic and thrombotic markers in infrequently transfused and frequently transfused beta-thalassemic patients.
Group NS with
infrequent blood 
transfusion
(n= 24)
Group NS with
frequent
blood transfusion 
(n=6)
Group S with 
infrequent blood 
transfusion 
(n=17)
Group S with 
frequent
blood transfusion
(n= 3)
F P 
   protein C (%) 70.25 (10.4)(53-92)
80.8 (3.8)
(76-86)
58.7 (19.1)a
(40-108)
62 (6)b
(58-69) 4.7 .005
   protein S (%) 71 (8.5)(59-83)
81.3 (2.5)
(78-85)
63 (15.9)
(48-100)
70 (7)b
(62-75) 4.2 .010
   TaT (μg/l) 12.58 (3.2)(9-20)
11.5 (2)
(9-15)
15.38 (3.7)a
(12.4-21)
16 (1.7)b
(15-18) 3.9 .014
   d-dimer 103 (ng/ml) 3.25 (1.6)(0-8)
2.3 (0.8)
(2-4)
5.3 (2.4)a
(0-8)
4.6 (1.1)b
(4-6) 5.7 .002
Values are mean (standard deviation). F=anOVa test (analysis of variance) for comparison of several means. ap<.05 for group S infrequently transfused with group nS infrequently 
transfused. bp<.05 for group S frequently transfused with group nS frequently transfused.
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Table 4. pulmonary hypertension* and platelet count in the groups.
Group NS with 
infrequent blood 
transfusion 
(n= 24)
Group NS with 
frequent blood 
transfusion 
(n=6)
Group S with 
infrequent blood 
transfusion 
(n=17)
Group S with 
frequent blood 
transfusion
(n= 3)
Tests of 
significance P 
   Pulmonary 
   hypertension
      n 3 0 16a 1 Chi-square32.36 <.001
      % 12.5 0.0 94.0 33.0 32.36 <.001
   Platelet count
      Mean (Sd) 278 (122) 211 (105) 783 (145)a 543 (123)b F
      range 144-425 134-370 523-955 365-745 59.42 <.001
*by doppler echocardiogram. aP<.001 group S infrequently transfused vs other groups. bP<.001 group S frequently transfused vs nS groups.
was a highly significant difference in the platelet count 
between S and NS groups (P<.001) with the highest 
platelet counts in the infrequently transfused S group. 
Platelet counts were normal in the NS group. There 
was significant negative correlation between protein C 
level in the whole population and both serum ferritin 
and TAT levels (P<.001), while there was no signifir
cant correlation between protein C and age, protein C 
and serum albumin, or protein C and AST (Figure 1).
DISCUSSIONS
Current therapeutic approaches have substantially pror
longed life expectancy in patients with thalassemia.12 A 
consequence of this is the appearance of new complir
cations. Venous thromboembolic events, such as pulr
monary embolism, deep venous thrombosis and portal 
vein thrombosis, have been observed.13r15 Several alterr
ations that indicate a state of activation of the hemor
static mechanisms have been described in thalassemia 
major.
 Protein C and protein S work together to inhibit 
the coagulation cascade. In our study, the levels of pror
tein C and protein S in the two patient groups were 
statistically lower than those in the control group rer
gardless of age. Similar results were obtained by Singer 
et al in Oakland, California,16 in studies of brthalasr
semia intermedia patients in Italy,17 and patients with 
brthalassemia major in Thailand and Turkey.18,19 
 Explanations for decreased levels of protein C and 
protein S in thalassemic patients include vitamin K 
deficiency, liver dysfunction due to hemosiderosis, and 
the increased turnover rate of protein C and protein 
S.20 In our study, no correlation was found between 
protein C levels in brthalassemia major patients and 
Figure 1. Correlation between protein C and other variables (age, albumin, ferritin, aST 
and TaT).
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the levels of serum transaminases or albumin, elimir
nating hepatic dysfunction as a cause of these alterar
tions. Shirahata et al19 found that liver damage was not 
the only cause of the reduction in these anticoagulant 
proteins. One alternative explanation for the significant 
reduction in protein C may be that this type of protein 
binds to phosphatidylserine, or other negatively charged 
phospholipids, abnormally present in the external memr
brane of the thalassemic erythrocytes.21
The reduction in protein C and S levels was signifir
cantly higher in splenectomized thalassemic patients 
rather than nonrsplenectomized ones. Consistent with 
this, Musumeci et al8 reported that the lowest values of 
protein C were found in older splenectomized patients. 
Also, these results are consistent with Shirahata et al19 
in his study on 48 patients with brthalassemia/hemor
globin E disease, brthalassemia major and hemoglobin 
E disease. In contrast to our results, Shebl et al22 found 
that there was no significant difference in protein C and 
protein S levels between splenectomized and nonrspler
nectomized patients with thalassemia major. The same 
was also reported by Cappellini et al17 in patients with 
thalassemia intermedia. The greater reduction in protein 
C and S levels in splenectomized thalassemic patients 
might be due to procoagulants on the surface of RBCs 
and abnormal platelets that are not removed from cirr
culation in the case of splenectomy,5 with the resultant 
consumption of protein C and protein S in an attempt 
to control the hypercoagulable state.
Our results showed that serum ferritin levels in the 
patients were high and negatively correlated with pror
tein C levels. Similar results were obtained in Italy by 
Musumeci et al8 on 74 thalassemic patients and in India 
by Naithani et al23 on 54 thalassemic patients. This can 
be explained by the fact that iron overload (reflected in 
high serum ferritin levels) leads to a state of chronic oxir
dative stress in patients with brthalassemia as evidenced 
by higher reactive oxygen species and lower reduced glur
tathione levels in platelets.24 This leads to platelet activar
tion, protein C and protein S consumption and susceptir
bility to the thromboembolic consequences.25 
 As a marker of coagulation activation, TAT levels 
were significantly increased in our patients. However, 
there was a marked increase in splenectomized rather 
than nonrsplenectomized patients. These findings indir
cate a lowrgrade hypercoagulable state. Similar results 
were obtained by Eldor et al,9 who found an elevated levr
el of TAT complexes in 50% of their brthalassemia mar
jor patients. In contrast, Cappellini et al17 reported that 
levels of coagulation activation markers were normal in a 
population of patients with thalassemia major. 
 As a manifestation of enhanced fibinolysis, our par
tients had high plasma Drdimer levels, particularly those 
who had been splenectomized. In studies conducted by 
Kemahli et al26 and Tripatara et al,27 Drdimer levels were 
increased, being highest in the splenectomized group 
while Naithani et al23 and Cappellini et al17 reported 
that Drdimers were similar in brthalassemic patients 
and controls. Increased plasma levels of TAT and Drdir
mer are suggestive of continuous thrombin generation 
and enhanced fibinolysis, leading to a subclinical process 
of thrombosis which could contribute to the pulmonary 
hypertension, low lung capacity, hypoxemia, and diffur
sion defects associated with right heart failure (cor pulr
monale)28 and to the high frequency of ischemic brain 
lesions associated with asymptomatic brain damage as 
detected by MRI.29 
 We also studied the impact of regularity of blood 
transfusion on the hypercoagulable state in our par
tients and found that levels of protein C and protein S 
were lower in infrequently transfused patients than in 
frequently transfused ones, while Drdimer levels were 
higher in infrequently transfused patients than frer
quently transfused ones. The same relationships were rer
ported by Eldor and Rachmilewitz.3 Also, Cappellini et 
al17 reported that there was a larger prevalence of venous 
thromboembolic events in transfusionrindependent par
tients with thalassemia intermedia (29%) than in regur
larly transfused patients with thalassemia major (2%). 
This was explained by the higher plasma levels of Drdir
mer and lower levels of naturally occurring anticoagur
lant proteins in transfusionrindependent patients with 
thalassemia intermedia than in regularly transfused par
tients with thalassemia major. As an additional or alterr
native mechanism of hypercoagulability in infrequently 
transfused patients, the role of thalassemic red cells was 
considered because protein C is adsorbed to the abnorr
mal red blood cell membrane of thalassemics, it is plaur
sibly accepted to be lower in those patients who are not 
on a transfusion program because most of their RBCs 
are of thalassemic nature capable of adsorbing protein C 
compared to those frequently transfused patients whose 
blood contains less of thalassemic red cells and more on 
normal RBCs.
 While pulmonary hypertension is increasingly recr
ognized as part of the clinical spectrum for brthalasr
semia, little is understood about the mechanisms and 
risk factors for its development. None of our patients 
had clinically manifest pulmonary hypertension, but 
Doppler echocardiograms revealed pulmonary hyperr
tension, defined as pulmonary artery systolic pressure 
more than 25 mm Hg in 20 patients (40%), and most of 
them (80%) belonged to the splenectomized and infrer
quently transfused group.
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 Our results are nearly identical with those reported by 
Singer et al16 where they found that 68% of their thalasr
semic patients had pulmonary hypertension by Doppler 
echocardiograms and most (94%) were splenectomized. 
Their higher percentages can be explained by the older 
age of their patients (26 [10] versus 12.1 [2.4] years in 
our study) and the higher percentage of splenectomized 
patients (72% versus 40% in our study).
 The lowest values of protein C and S were observed 
in the splenectomized and infrequently transfused group, 
which explains the higher percentage of pulmonary hyr
pertension in these patients. Also, we investigated the 
role of postsplenectomy thrombocytosis and found that 
there was a significant difference in the platelet count ber
tween splenectomized and nonrsplenectomized groups 
(P<.001) with the highest platelet counts observed in 
the splenectomized and infrequently transfused group. 
Similar results were obtained by Singer et al16 who also 
found that postsplenectomy thrombocytosis was correr
lated with evidence of pulmonary hypertension in their 
patients.
In conclusion, protein C levels were significantly 
reduced in thalassemic patients, especially among spler
nectomized and infrequently transfused ones, indicatr
ing a major role for protein C in the hypercoagulable 
state in those patients. These findings raise the issue as 
to whether it would be costrbeneficial to recommend 
prophylactic antithrombotic therapy in highrrisk thalasr
semic patients. A wider prospective study will be necesr
sary to delineate under which circumstances this might 
be implicated, and at what level of protein C deficiency 
to start prophylactic antithrombotic therapy.
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